Updated:
H&D Asset Management
H&D Asset Management was founded in 2016 in Taipei, Taiwan, by co-founder Grace Chen alongside a partner team that includes Bobby Chu, Powei Chu, and...
H&D Asset Management
H&D Asset Management was founded in 2016 in Taipei, Taiwan, by co-founder Grace Chen alongside a partner team that includes Bobby Chu, Powei Chu, and Cheng-Wei Chu. The firm describes itself as anchored in traditional industry roots and backed by a select group of individual shareholders (per firm website). The firm invests across pre-IPO and early-stage companies in digital and biotechnology sectors, often as a limited partner in venture capital funds. Confirmed portfolio holdings include BlossomHill Therapeutics (a San Diego-based oncology and autoimmune drug discovery company), ClearMind (a maker of minimally invasive surgical devices for intracerebral hemorrhage), and Renxin Pharmaceuticals (which holds FDA rare pediatric disease designation for Stargardt disease). On the tech side, H&D backs companies in encryption key management — one acquired by Circle in 2022 — as well as GPU-based RAID storage and 3D industrial sensors. Its geographic reach spans Taiwan, mainland China, the US, Singapore, Hong Kong, Europe, and India. The firm maintains a team of over 20 named professionals including investment managers, legal, finance, and secretarial staff. Additional offices are located in Taichung, Taiwan. H&D also engages in securities trading markets, futures and options, bonds, funds, and equity-oriented securities, as disclosed on its website. The firm has not publicly disclosed AUM or recent deployment activity. A structural differentiator is H&D's hybrid model: while primarily operating as a limited partner in venture funds for direct startup exposure, the firm also dedicates significant resources to public-market securities including futures and options. This dual approach — combining private equity LP commitments with active trading strategies — is relatively rare among Taiwan-based asset managers.
General information
Firm type
Private Equity
Year founded
2016
AUM
Undisclosed
Location
Region
Asia
Country
Taiwan
City
Taipei
Corporate office
10F, No. 42, Section 2, Zhongshan N Rd, Zhongshan District, Taipei City, 10491, Taiwan
Additional offices
10 F.-1, No. 88, Sec. 1, Huizhong Rd., Xitun Dist., Taichung City 407025, Taiwan
Principals
Grace Chen
Co-Founder
Bobby Chu
Partner
Powei Chu
Partner
Cheng-Wei Chu
Partner
Samuel Cheng
High Tech
Sector focus
Frequently asked questions
Who runs investment decisions at H&D Asset Management?
Co-founder Grace Chen leads the firm alongside partners Bobby Chu, Powei Chu, and Cheng-Wei Chu. The investment team includes high-tech focused Samuel Cheng, biomedical vice presidents Serena Hsu and PH Hsieh, and stock trading executive John Yang, among others (per firm website).
How does H&D Asset Management structure its investments?
H&D typically operates as a Limited Partner in venture capital funds, focusing on pre-IPO or early-stage digital and biotechnology companies. It also invests directly in securities trading markets, futures, options, bonds, funds, and equity-oriented securities, giving it a hybrid private-public investment posture (per firm website).
What sectors does H&D Asset Management target?
The firm focuses on AI and cloud computing, smart manufacturing, biotech and healthcare, cybersecurity, and Web3. Confirmed portfolio companies include BlossomHill Therapeutics (oncology/autoimmune), ClearMind (minimally invasive neurosurgery), and Renxin Pharmaceuticals (Stargardt disease) (per firm website).
Does H&D Asset Management participate in fund commitments or only direct deals?
H&D operates primarily as a Limited Partner in venture capital funds, committing capital to early-stage and pre-IPO ventures. It also makes direct investments in public securities including equities, futures, and bonds — a dual structure disclosed on its website.
Where does the underlying wealth for H&D Asset Management come from?
The firm states it is backed by a select group of individual shareholders and has roots in traditional industry, but it does not publicly disclose the specific source of its capital or any family-office affiliation (per firm website).
What is H&D Asset Management's geographic footprint for investments?
H&D invests across Asia and globally, including Taiwan, mainland China, the United States, Singapore, Hong Kong, Europe, and India. Its portfolio includes a San Diego-based biotech firm and a company acquired by financial technology firm Circle (per firm website).
How is H&D Asset Management related to any larger corporate structure?
The firm does not publicly disclose a parent company or affiliation with a larger group. It describes itself as a legally registered investment firm in Taipei with roots in traditional industry and a select group of individual shareholders (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: